Additionally, neither cycloheximide (CHX) nor the proteasome inhibitor MG132 altered UBE2T protein levels in BA‐treated glioma cells (Figure 3I), thereby ruling out protein degradation. This evidence concerns the gene UBE2T and central nervous system cancer.